Bolt Biotherapeutics, Inc. (BOLT) News
Filter BOLT News Items
BOLT News Results
|Loading, please wait...|
BOLT News Highlights
- For BOLT, its 30 day story count is now at 3.
- Over the past 19 days, the trend for BOLT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AIM, ALX and DRUG are the most mentioned tickers in articles about BOLT.
Latest BOLT News From Around the Web
Below are the latest news stories about Bolt Biotherapeutics Inc that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present at two upcoming conferences in February: Guggenheim 2022 Oncology Virtual ConferenceFireside chat on Wednesday, Feb. 9, at 10:00 a.m. PT (1:00 p.m. ET)Virtual 1
Penny stocks are incredibly risky and should only be considered with speculation funds.
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor OPDIVO® (nivolumab). In parallel, Bolt continues to advance the single-agent portion of the study, following the presentation of interim dose-escalation data at the European Society of Medical Oncology Immuno-Oncology (ESMO I-O) Congres...
Penny stocks are defined as stocks that trade at less than $5 a share. While penny stocks continue to be a risky bet, they are still popular among investors. These stocks may be volatile, but with due diligence, some hidden treasures may be found. Such penny stocks trading at low share prices can translate to huge gains for retail investors in terms of percentage returns. Using the TipRanks penny stock screener, let us find some of the top penny stocks. Bolt Biotherapeutics (NASDAQ: BOLT) The first one on this list is Bolt Biotherapeutics, a clinical-stage biotechnology company founded in 2015 by Dr. Edgar G. Engleman of Stanford University.
Disappointing news for Aeglea BioTherapeutics (NASDAQ: AGLE), Bolt Biotherapeutics (NASDAQ: BOLT), and Reata Pharmaceuticals (NASDAQ: RETA) caused shares of all three companies to plunge. In this Motley Fool Live video, recorded on Dec. 8, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether any of these three biotech stocks are now bad-news buys.
REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021.
SVB Leerink reaffirmed their buy rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research report report published on Thursday morning, Price Targets.com reports. A number of other research analysts have also weighed in on BOLT. Zacks Investment Research raised Bolt Biotherapeutics from a sell rating to a hold rating in a research report on […] The post SVB Leerink Reaffirms Buy Rating for Bolt Biotherapeutics (NASDAQ:BOLT) appeared first on ETF Daily News .
Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective increased by Stifel Nicolaus from $19.00 to $34.00 in a research report report published on Monday morning, The Fly reports. Stifel Nicolaus currently has a buy rating on the stock. The analysts noted that the move was a valuation call. A number of other equities analysts also recently